|
Group
|
Total (cases)
|
Continuation of TKI [cases (%)]
|
AZD9291 [cases (%)]
|
Chemo ± RT [cases (%)]
|
TKI plus chemo/RT [cases (%)]
|
BSC [cases (%)]
|
|---|
|
CF
|
|
T790M+
|
72
|
23 (31.9)
|
28 (38.9)
|
10 (13.9)
|
4 (5.6)
|
7 (9.7)
|
|
T790M−
|
103
|
41 (39.8)
|
23 (22.3)
|
21 (20.4)
|
9 (8.7)
|
9 (8.7)
|
|
Total
|
175
|
64 (36.6)
|
51 (29.1)
|
31 (17.7)
|
13 (7.4)
|
16 (9.1)
|
|
BF
|
|
T790M+
|
6
|
1 (16.7)
|
1 (16.7)
|
0 (0)
|
0 (0)
|
4 (66.7)
|
|
T790M−
|
21
|
9 (42.9)
|
3 (14.3)
|
2 (9.5)
|
2 (9.5)
|
5 (23.8)
|
|
Total
|
27
|
10 (37.0)
|
4 (14.8)
|
2 (7.4)
|
2 (7.4)
|
9 (33.3)
|
|
OF
|
|
T790M+
|
53
|
10 (18.9)
|
22 (41.5)
|
11 (20.8)
|
4 (7.5)
|
6 (11.3)
|
|
T790M−
|
23
|
7 (30.4)
|
8 (34.8)
|
3 (13)
|
1 (4.3)
|
4 (17.4)
|
|
Total
|
76
|
17 (22.4)
|
30 (39.5)
|
14 (18.4)
|
5 (6.6)
|
10 (13.2)
|
- CF, progressive disease limited to the chest in lung/pleural tissues and lymph nodes, with no evidence of progression beyond the chest; BF, progressive disease in a previously existing site or a new site of metastatic disease in the brain, with no evidence of extracranial progression; OF, progressive disease in other distant sites or multiple sites including the chest and intracranial region
- TKI tyrosine kinase inhibitor, Chemo chemotherapy, RT radiotherapy, BSC best supportive care
